Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

97 results about "T-type calcium channel" patented technology

T-type calcium channels are low voltage activated calcium channels that become deinactivated during cell membrane hyperpolarization but then open to depolarization. The entry of calcium into various cells has many different physiological responses associated with it. Within cardiac muscle cell and smooth muscle cells voltage-gated calcium channel activation initiates contraction directly by allowing the cytosolic concentration to increase. Not only are T-type calcium channels known to be present within cardiac and smooth muscle, but they also are present in many neuronal cells within the central nervous system. Different experimental studies within the 1970s allowed for the distinction of T-type calcium channels (transient opening calcium channels) from the already well-known L-type calcium channels (Long-Lasting calcium channels). The new T-type channels were much different from the L-type calcium channels due to their ability to be activated by more negative membrane potentials, had small single channel conductance, and also were unresponsive to calcium antagonist drugs that were present. These distinct calcium channels are generally located within the brain, peripheral nervous system, heart, smooth muscle, bone, and endocrine system.

Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof

The present invention provides for novel piperazinylalkylpyrazole derivatives, the preparation method thereof and the selective T-type calcium channel blocking activity thereof. Particularly, it provides a piperazinylalkylpyrazole derivative as represented by the formula set forth below or its pharmaceutically acceptable salts, and its preparation method thereof. The compound of Formula 1 is a novel piperazinylalkylpyrazole derivative, which particulary has T-type Ca2+ channel blocking effect and thus can be useful as a therapeutic agent for nerve and muscle pain.
Owner:KOREA INST OF SCI & TECH

Enhancement of sleep with t-type calcium channel antagonists

InactiveUS20060003985A1Enhancing and improving sleep qualityImprove sleep efficiencyBiocideAnimal repellantsT-type calcium channelAntagonist
A T-type calcium channel antagonist is useful, alone or in combination with other agents, for inducing sleep and enhancing and improving the quality of sleep, in particular by increasing sleep efficiency and augmenting sleep maintenance.
Owner:RENGER JOHN J +1

Method of resistance of epilepsy by suppressing the function of alpha 1g protein

InactiveUS20060025397A1Suppressing functionResisting epilepsyOrganic active ingredientsHeavy metal active ingredientsKnockout animalSuppressor
The disclosure concerns a method for resistance of epilepsy by suppressing the function of alpha 1 G protein of T-type calcium channels, use of suppressor of alpha 1 G protein for prevention or treatment for epilepsy, knockout mice resisting epilepsy by disrupting alpha 1 G subunit of T-type calcium channel, and preparation method thereof. In addition, suppressing alpha 1 G protein of T-type calcium channels does not occur epilepsy, and alpha 1 G-deficient mice are useful to study of mechanism related to epilepsy.
Owner:POHANG UNIV OF SCI & TECH +1

Anti-metastatic ability of mibefradil and gadolinium

The present invention relates to methods for inhibiting tumor cell metastasis in cancer comprising administering a composition comprising a T-type calcium channel inhibitor, such as mibefradil.
Owner:RGT UNIV OF MICHIGAN

Diaryl-cyclylalkyl derivatives as calcium channel blockers

InactiveUS20090270338A1High activityNervous disorderOrganic chemistryT-type calcium channelCalcium channel activity
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and / or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted N-cyclylalkyl-diphenylpropanamide derivatives as shown in formula (1).
Owner:ZALICUS PHARMA LTD (CA)

Heterocycle amide t-type calcium channel antagonists

The present invention is directed to heterocycle amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
Owner:BARROW JAMES C +3

Di-t-butylphenyl piperazines as calcium channel blockers

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and / or T-type calcium channel activity are disclosed. Specifically, a series of compounds containing di-t-butyl phenyl piperazine derivatives of the general formula (1).
Owner:ZALICUS PHARMA LTD (CA)

Isoxazole derivatives as calcium channel blockers

Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of isoxazole containing compounds are disclosed of the general formula (1) where Z is N or CHNR3 and (Ar1)2CR4 is optionally substituted benzhydryl.
Owner:ZALICUS PHARMA LTD (CA)

Cyclylamine derivatives as calcium channel blockers

InactiveUS20090270394A1Enhance calcium channel blocking activityHigh activityOrganic active ingredientsOrganic chemistryT-type calcium channelCalcium channel activity
Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type and / or T-type calcium channel activity are disclosed. Specifically, a series of compounds of substituted or unsubstituted cyclylamine derivatives as shown in formulas (1).
Owner:ZALICUS PHARMA LTD (CA)

Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation thereof

Disclosed are isoindolinone derivatives, represented by Chemical Formula 1, having inhibitory activity against T-type calcium channels, pharmaceutically acceptable salts thereof, a preparation method thereof, and a pharmaceutical composition comprising the same as an active ingredient.wherein R1˜R6 are as defined in the specification.
Owner:KOREA INST OF SCI & TECH

T Type Calcium Channel Blockers and the Treatment of Diseases

The present invention provides a method for treating a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, which comprises administering to the mammal a therapeutically effective amount of a T type calcium channel inhibitor, a prodrug thereof, or a pharmaceutically acceptable salt of said inhibitor or prodrug, wherein the T type calcium channel inhibitor has a structure represented by Formula (I): Formula (I), wherein R1 is selected from the group consisting of C1-C4 alkyl, hydroxy and C1-C4 alkoxy; X is selected from the group consisting of N and CH; Z is selected from the group consisting of NH, O, S and CH2; R2 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy; and R3 is selected from the group consisting of H, halo, NH2, C1-C4 alkyl, hydroxy and C1-C4 alkoxy. In one embodiment R1 is selected from the group consisting of C1-C4 alkyl, hydroxyl and C1-C4 alkoxy, X is N, Z is O or CH2, R2 is H, halo, NH2 or hydroxyl and R3 is H.
Owner:UNIV OF VIRGINIA ALUMNI PATENTS FOUND

Pyridyl Amide T-Type Calcium Channel Antagonists

The present invention is directed to pyridyl amide compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
Owner:MERCK SHARP & DOHME LLC

Transgenic mouse whose genome comprises a homozygous disruption of its alpha1G gene, a method of preparing the same and use thereof

The disclosure concerns a method for resistance of epilepsy by suppressing the function of alpha 1G protein of T-type calcium channels, use of suppressor of alpha 1G protein for prevention or treatment for epilepsy, knockout mice resisting epilepsy by disrupting alpha 1G subunit of T-type calcium channel, and preparation method thereof. The α1G-knockout transgenic mouse can be used for investigating the relationship between diseases particularly neuropathy or psychopathy and the function of α1G T-type calcium channel via various behavioral tests since α1G subunit is mainly expression in central nervous system (CNS) and pheripheral nervous system (PNS). Further, the α1G-knockout transgenic mouse can be used for screening antileptic agents.
Owner:ORIENTBIO

Methods for treating angelman syndrome and related disorders

Provided herein are methods of treating Angelman Syndrome and / or Prader-Willi syndrome, that include administering an effective amount of a T-type calcium channel antagonist to a subject in need of the treatment.
Owner:CAVION INC

Quinazolinone T-Type Calcium Channel Antagonists

The present invention is directed to quinazolinone compounds which are antagonists of T-type calcium channels, and which are useful in the treatment or prevention of disorders and diseases in which T-type calcium channels are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which T-type calcium channels are involved.
Owner:MERCK SHARP & DOHME LLC

Fused imidazole derivative

InactiveUS20130065896A1Excellent T-type calcium channel antagonistic effectImprove securityBiocideOrganic chemistryHydrogen atomT-type calcium channel
Provided is a novel compound which shows an antagonistic effect against T-type calcium channels, and is useful as a pharmaceutical product.A compound represented by general formula (I), and a pharmaceutical agent containing the same, are disclosed:wherein n represents the number of nitrogen atoms contained in the 6-membered fused aromatic ring, and is 0, 1 or 2; p represents the number of nitrogen atoms contained in the 6-membered aromatic ring, and is 0 or 1; X represents an oxygen atom, —SO2— or —N(R9)—; and R1 to R5 each represents a hydrogen atom or other substituents.
Owner:TOAEIYO

Derivatives of 1-phenoxy propan-2-ol and pharmaceutical composition containing the same

The present invention relates to a novel phenoxypropanol derivative, use thereof for blocking T-type calcium channel and / or TREK channel, and use thereof for preventing and / or treating T-type calcium channel- and / or TREK channel-associated diseases.
Owner:KOREA INST OF SCI & TECH

Method for recording T type calcium channel current by separating and cultivating newborn rat cortical neural cells

The invention provides a method for recording T type calcium channel current by separating and cultivating newborn rat cortical neural cells, and stably cultivated newborn rat cortical neural cells have a normal T type calcium ion channel function. The method is suitable to research on the physiological and pharmacological characteristics of the rat cortical neural cells by a patch clamp technique. The experiment operation is easy to master, and the method for stably cultivating the separated newborn rat cortical neural cells is simple and efficient. The success rate, the stability and the repeatability of an experiment are increased apparently by means of stably cultivating the separated newborn rat cortical neural cells.
Owner:辉源生物科技(上海)有限公司

Mice lacking alpha 1g showing enhanced novelty-seeking and alcohol preference and therapeutic methods for mood disorders by modulating alpha 1g t-type calcium channels

The present invention relates to a novel use of an α1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in α1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous disease model for human nervous related diseases such as novelty-seeking character, alcoholism, anxiety and emotion disorder by stress, etc. The α1G T-type channel transgenic mice showing novelty-seeking and alcohol preference of the present invention can be effectively used for the development of a medicine and a therapeutic method for human nervous diseases.
Owner:KOREA INST OF SCI & TECH

Method for treating central pain syndrom or for inducing centrally generated pain in an animal model

The present invention provides a method for treating central pain syndrome in a mammal by administering an effective amount of a thalamic anticonvulsant compound. Also provided are methods for inducing centrally generated pain responses in an animal model and for screening and identifying a compound that inhibits T-type calcium channels.
Owner:UNIV OF MARYLAND

3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same

The present invention relates to 3,4-dihydroquinazoline derivatives as T-type calcium channel blockers and a method of preparing the same. The present invention further relates to a composition comprising the same. The composition comprising the 3,4-dihydroquinazoline derivatives of the present invention can be effectively used for preventing and treating angina pectoris, high blood pressure, myocardial disease, pain and epilepsy by blocking the T-type calcium channel.
Owner:KOREA INST OF SCI & TECH

Method for the prevention and treatment of essential tremor by regulating alpha1g t-type calcium channel or by t-type calcium channel blockers

The present invention relates to a method for the prevention and treatment of essential tremor by blocking α1G T-type calcium channel, a preventive and therapeutic agent for essential tremor containing the α1G T-type calcium channel blocker as an active ingredient, and a screening method of a preventive and therapeutic agent for essential tremor by investigating α1G T-type calcium channel blocking activity. More precisely, the present invention relates to a method for the prevention and treatment of essential tremor by using α1G T-type calcium channel blocker, for which the inventors confirmed that the α1G T-type calcium channel knock out mice (α1G − / −) had resistance against essential tremor and when the T-type channel blocker was administered to the wild type mice (α1G + / +), they gained resistance against essential tremor.
Owner:KOREA ADVANCED INST OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products